{"id":"bevacizumab-pemetrexed-carboplatin","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Neutropenia"},{"rate":"30-40","effect":"Anemia"},{"rate":"20-30","effect":"Thrombocytopenia"},{"rate":"30-40","effect":"Fatigue"},{"rate":"20-30","effect":"Nausea/vomiting"},{"rate":"10-20","effect":"Peripheral neuropathy"},{"rate":"5-10","effect":"Bleeding events"},{"rate":"10-20","effect":"Hypertension"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Bevacizumab is a VEGF inhibitor that starves tumors of blood supply by blocking angiogenesis. Pemetrexed and carboplatin are platinum-based chemotherapy agents that work through different mechanisms—pemetrexed inhibits folate-dependent enzymes while carboplatin causes DNA cross-linking—providing complementary cytotoxic activity against rapidly dividing cancer cells.","oneSentence":"This combination uses a monoclonal antibody to block tumor blood vessel formation while two chemotherapy agents work synergistically to kill cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:04:09.068Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-squamous non-small cell lung cancer (NSCLC), first-line metastatic disease"}]},"trialDetails":[{"nctId":"NCT05001880","phase":"PHASE2","title":"Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-03-22","conditions":"Peritoneal Malignant Mesothelioma","enrollment":66},{"nctId":"NCT06704724","phase":"PHASE1","title":"A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2024-12-10","conditions":"Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung","enrollment":30},{"nctId":"NCT05751187","phase":"PHASE2","title":"Pembrolizumab Plus Bevacizumab and Chemotherapy for Non-Squamous NSCLC Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Chest Hospital","startDate":"2023-06-27","conditions":"Non-squamous NSCLC","enrollment":54},{"nctId":"NCT03178552","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2017-09-22","conditions":"Non-Small Cell Lung Cancer","enrollment":1000},{"nctId":"NCT05083481","phase":"PHASE1, PHASE2","title":"A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2021-10-19","conditions":"Advanced Solid Tumors","enrollment":366},{"nctId":"NCT06447662","phase":"PHASE1","title":"A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.","status":"RECRUITING","sponsor":"Pfizer","startDate":"2024-06-27","conditions":"Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung","enrollment":330},{"nctId":"NCT07420439","phase":"PHASE2","title":"Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease","status":"NOT_YET_RECRUITING","sponsor":"Intergroupe Francophone de Cancerologie Thoracique","startDate":"2026-05-15","conditions":"Non Small Cell Lung Cancer Metastatic, Interstitial Lung Disease (ILD)","enrollment":108},{"nctId":"NCT04837716","phase":"PHASE1","title":"Ensartinib, Carboplatin, Pemetrexed and Bevacizumab for the Treatment of Stage IIIC or IV or Recurrent ALK-Positive Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-03-18","conditions":"Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IIIC Lung Cancer AJCC v8","enrollment":12},{"nctId":"NCT07416058","phase":"PHASE2","title":"PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Guangdong Association of Clinical Trials","startDate":"2026-01-31","conditions":"Lung Adenocarcinoma","enrollment":61},{"nctId":"NCT06783647","phase":"PHASE2","title":"A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]","status":"RECRUITING","sponsor":"Nanjing Leads Biolabs Co.,Ltd","startDate":"2025-06-11","conditions":"Advanced Solid Tumour","enrollment":230},{"nctId":"NCT03337698","phase":"PHASE1, PHASE2","title":"A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-12-27","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":314},{"nctId":"NCT03307785","phase":"PHASE1","title":"Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042","status":"COMPLETED","sponsor":"Tesaro, Inc.","startDate":"2017-10-12","conditions":"Neoplasms, Metastatic Cancer, Advanced Cancer","enrollment":60},{"nctId":"NCT04185883","phase":"PHASE1","title":"Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amgen","startDate":"2019-12-17","conditions":"Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation","enrollment":610},{"nctId":"NCT03520686","phase":"PHASE3","title":"Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2018-05-18","conditions":"Non Small Cell Lung Cancer","enrollment":1538},{"nctId":"NCT07001618","phase":"PHASE2","title":"Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2025-09","conditions":"NSCLC (Advanced Non-small Cell Lung Cancer)","enrollment":162},{"nctId":"NCT03762018","phase":"PHASE3","title":"BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma","status":"COMPLETED","sponsor":"ETOP IBCSG Partners Foundation","startDate":"2019-04-30","conditions":"Pleural Mesothelioma Malignant Advanced","enrollment":401},{"nctId":"NCT06839105","phase":"PHASE1","title":"A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies","status":"RECRUITING","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2025-02-21","conditions":"Non-Small Cell Lung Cancer, Colorectal Cancer, Renal Cell Carcinoma, Melanoma and Other Solid Tumor","enrollment":214},{"nctId":"NCT04042558","phase":"PHASE2","title":"A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies","status":"COMPLETED","sponsor":"Centre Francois Baclesse","startDate":"2019-09-26","conditions":"NSCLC Stage IIIB, NSCLC Stage IV, EGFR Gene Mutation","enrollment":150},{"nctId":"NCT03786692","phase":"PHASE2","title":"Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC","status":"RECRUITING","sponsor":"Fox Chase Cancer Center","startDate":"2019-09-04","conditions":"Non-Small Cell Carcinoma of Lung, TNM Stage 4","enrollment":117},{"nctId":"NCT04512430","phase":"PHASE2","title":"Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients","status":"TERMINATED","sponsor":"Fundación GECP","startDate":"2020-12-02","conditions":"Non Small Cell Lung Cancer, EGFR Gene Mutation","enrollment":4},{"nctId":"NCT06775275","phase":"PHASE2","title":"A Study of Adebrelimab in Combination with Chemo with or Without Bevacizumab Neoadjuvant Therapy for Resectable NSCLC","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Guangzhou Medical University","startDate":"2024-09-24","conditions":"Resectable Lung Non-Small Cell Carcinoma","enrollment":60},{"nctId":"NCT04245085","phase":"PHASE2","title":"ABC-lung: Atezolizumab, Bevacizumab and Chemotherapy in EGFR-mutant Non-small Cell Lung Carcinoma","status":"COMPLETED","sponsor":"ETOP IBCSG Partners Foundation","startDate":"2020-09-29","conditions":"EGFRmutant Stage IIIB/C or IV Non-squamous NSCLC","enrollment":95},{"nctId":"NCT03872661","phase":"PHASE2","title":"Neoadjuvant IBI308, Bevacizumab, Plus Pemetrexed and Carboplatin Followed by Surgery in Unresectable Stage III NSCLC","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2019-03-01","conditions":"Lung Cancer Stage III","enrollment":36},{"nctId":"NCT02794571","phase":"PHASE1","title":"Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2016-05-23","conditions":"Advanced/Metastatic Tumors","enrollment":518},{"nctId":"NCT04973293","phase":"NA","title":"Preoperative Sintilimab Combined With Bevacizumab and Chemotherapy for Resectable Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2022-10-01","conditions":"Lung Neoplasm Malignant","enrollment":20},{"nctId":"NCT04194203","phase":"PHASE3","title":"A Study of Bevacizumab, Carboplatin, and Paclitaxel or Pemetrexed With or Without Atezolizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (IMpower151)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2020-04-09","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":305},{"nctId":"NCT04322578","phase":"PHASE2","title":"Crizotinb or Standard Chemotherapy in Met Exon 14 Skipping Advanced NSCLC","status":"RECRUITING","sponsor":"Hunan Province Tumor Hospital","startDate":"2020-03-24","conditions":"Non-small Cell Lung Cancer","enrollment":120},{"nctId":"NCT04147351","phase":"PHASE2","title":"A Phase II Study of Atezolizumab in Combination With Bevacizumab, Carboplatin or Cisplatin, and Pemetrexed for EGFR-mutant Metastatic Non-small Cell Lung Cancer Patients After Failure of EGFR Tyrosine Kinase Inhibitors.","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2020-04-10","conditions":"NSCLC Stage IIIB~IV","enrollment":22},{"nctId":"NCT06334757","phase":"PHASE2","title":"Serplulimab Plus Bevacizumab and Chemotherapy for EGFR-mutant Metastatic NSCLC Patients After EGFR-TKI Treatment Failure","status":"UNKNOWN","sponsor":"Henan Cancer Hospital","startDate":"2023-05-08","conditions":"Non-Squamous Non-Small Cell Lung Cancer","enrollment":46},{"nctId":"NCT05930665","phase":"PHASE2","title":"Study of Cadonilimab Combined With Bevacizumab and Standard Chemotherapy as First Line Therapy in Unresectable Pleural Mesothelioma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-11-01","conditions":"Pleural Mesothelioma","enrollment":38},{"nctId":"NCT05329025","phase":"PHASE2","title":"A Study of QL1706 Combined With Chemotherapy in Advanced Non-small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2022-06-01","conditions":"Non-small-cell Lung Cancer","enrollment":100},{"nctId":"NCT05812534","phase":"PHASE2","title":"Study of Cadonilimab Combined With Bevacizumab and Chemotherapy for Advanced Nonsquamous Non-small Cell Lung Cancer Patients With Untreated Brain Metastases","status":"UNKNOWN","sponsor":"Second Affiliated Hospital of Nanchang University","startDate":"2023-12","conditions":"Non Small Cell Lung Cancer, Brain Metastases","enrollment":36},{"nctId":"NCT03952403","phase":"PHASE3","title":"A Study of HLX10 in Combination With Carboplatin Plus (+) Pemetrexed With or Without HLX04 Compared With Carboplatin+Pemetrexed in 1L Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC)","status":"UNKNOWN","sponsor":"Shanghai Henlius Biotech","startDate":"2019-12-02","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":643},{"nctId":"NCT01107626","phase":"PHASE3","title":"Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2010-10-25","conditions":"Lung Cancer","enrollment":1516},{"nctId":"NCT03991403","phase":"PHASE3","title":"Study of Atezolizumab Combination Carboplatin + Paclitaxel + Bevacizumab in EGRF Mutation or ALK Translocation NSCLC","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2019-08-27","conditions":"Non-small Cell Lung Cancer","enrollment":228},{"nctId":"NCT05267366","phase":"PHASE2","title":"Chemotherapy Combines With Bevacizumab and PD-1 Inhibitor in Non-squamous NSCLC","status":"UNKNOWN","sponsor":"Qingdao Central Hospital","startDate":"2022-02-01","conditions":"PFS, OS","enrollment":117},{"nctId":"NCT01705184","phase":"PHASE2","title":"Re-introduction of Pemetrexed and Cisplatin With Prolonged Angiogenic Blocking by Bevacizumab in Advanced Lung Cancer.","status":"COMPLETED","sponsor":"Intergroupe Francophone de Cancerologie Thoracique","startDate":"2012-12","conditions":"Non-small Cell Lung Cancer Metastatic, Nonsquamous Nonsmall Cell Neoplasm of Lung","enrollment":120},{"nctId":"NCT03713944","phase":"PHASE2","title":"Carboplatin Plus Pemetrexed Plus Atezolizumab Plus Bevacizumab in Chemotherapy and Immunotherapy-naïve Patients With Stage IV Non-squamous Non-small Cell Lung Cancer","status":"TERMINATED","sponsor":"Nasser Hanna","startDate":"2018-11-15","conditions":"NSCLC Stage IV, NSCLC, Recurrent","enrollment":30},{"nctId":"NCT05675033","phase":"PHASE2","title":"Serplulimab Combined With Anti-VEGF Antibody in Advanced Lung Adenocarcinoma","status":"UNKNOWN","sponsor":"Fujian Cancer Hospital","startDate":"2023-01-10","conditions":"Lung Adenocarcinoma, Stage IV Non-small Cell Lung Cancer, PD-1 Inhibitor","enrollment":50},{"nctId":"NCT00312728","phase":"PHASE2","title":"A Study of Bevacizumab in Combination With First- or Second-Line Therapy in Subjects With Treated Brain Metastases Due to Non-Squamous NSCLC (PASSPORT)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2006-03","conditions":"Non-Small Cell Lung Cancer, Brain Neoplasms","enrollment":115},{"nctId":"NCT02039674","phase":"PHASE1, PHASE2","title":"A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-02-21","conditions":"Non-small Cell Lung Carcinoma","enrollment":267},{"nctId":"NCT04861948","phase":"PHASE1","title":"IBI188 Combination Therapy in Solid Tumors","status":"TERMINATED","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2021-05-25","conditions":"Solid Tumors, Lung Adenocarcinoma, Osteosarcoma","enrollment":9},{"nctId":"NCT05334277","phase":"PHASE2","title":"Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2022-05-06","conditions":"Non-small Cell Lung Cancer","enrollment":280},{"nctId":"NCT05507606","phase":"PHASE2","title":"Study of Osimertinib+Bevacizumab+Chemotherapy for EGFR+ Advanced Non-Small Cell Lung Cancer With Concurrent Mutations","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2021-08-01","conditions":"Non Small Cell Lung Cancer","enrollment":50},{"nctId":"NCT00456261","phase":"PHASE2","title":"First-Line Treatment of A Comparison of 2 Treatments in Elderly Patients With Advanced NSCLC","status":"COMPLETED","sponsor":"SCRI Development Innovations, LLC","startDate":"2007-03","conditions":"Lung Cancer","enrollment":110},{"nctId":"NCT02743923","phase":"PHASE3","title":"Cisplatin-Pemetrexed Compared With Carboplatin-Paclitaxel-Bevacizumab in KRAS Mutated Non-small Cell Lung Cancer","status":"UNKNOWN","sponsor":"The Netherlands Cancer Institute","startDate":"2016-04","conditions":"Carcinoma, Non-Small Cell Lung","enrollment":203},{"nctId":"NCT05132413","phase":"PHASE3","title":"A Study of SHR-1701 Plus Bevacizumab and Chemotherapy in Non-Small-Cell-Lung-Cancer","status":"UNKNOWN","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2021-12-30","conditions":"Advanced or Metastatic Non-squamous Non-small-cell Lung Cancer","enrollment":561},{"nctId":"NCT04405674","phase":"PHASE2","title":"Tislelizumab Combined With Chemotherapy With or Without Bevacizumab in TKI-Resistant EGFR-Mutated Non-squamous NSCLC","status":"UNKNOWN","sponsor":"Shanghai Chest Hospital","startDate":"2020-07-15","conditions":"Non Small Cell Lung Cancer","enrollment":120},{"nctId":"NCT00402883","phase":"PHASE2","title":"Chemotherapy, Radiotherapy and Bevacizumab in Patients With Unresectable Stage III Non-Small-Cell Lung Cancer","status":"TERMINATED","sponsor":"SCRI Development Innovations, LLC","startDate":"2006-11","conditions":"Lung Cancer","enrollment":5},{"nctId":"NCT00948675","phase":"PHASE3","title":"Study of Participants With Advanced Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2009-09-01","conditions":"Advanced Non-Small Cell Lung Cancer","enrollment":361},{"nctId":"NCT01454102","phase":"PHASE1","title":"Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2011-12-16","conditions":"Non-small Cell Lung Cancer","enrollment":472},{"nctId":"NCT00533429","phase":"PHASE2","title":"Study of Pemetrexed + Carboplatin + Bevacizumab + Enzastaurin Versus Pemetrexed + Carboplatin + Bevacizumab + Placebo in Participants With Non-Small Cell Lung Cancer Who Have Not Been Previously Treated With Chemotherapy","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2007-10","conditions":"Non-small Cell Lung Cancer","enrollment":40},{"nctId":"NCT02574078","phase":"PHASE1, PHASE2","title":"A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2015-11-23","conditions":"Non-Small Cell Lung Cancer","enrollment":341},{"nctId":"NCT01633970","phase":"PHASE1","title":"A Study of Atezolizumab Administered in Combination With Bevacizumab and/or With Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2012-07-11","conditions":"Cancer","enrollment":240},{"nctId":"NCT04517526","phase":"PHASE2","title":"Efficacy and Safety of Platinum-based Chemotherapy + Bevacizumab + Durvalumab, and Salvage SBRT for IV Non-Small Cell Lung Cancer Patients With EGFR Mutations After Failure of First Line Osimertinib: A Multicenter, Prospective, Phase II Clinical Study","status":"UNKNOWN","sponsor":"Shanghai Cancer Hospital, China","startDate":"2020-11-01","conditions":"Lung Cancer Stage IV，EGFR-mutant，TKI，PD-L1，SBRT","enrollment":60},{"nctId":"NCT01803282","phase":"PHASE1","title":"Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2013-03-29","conditions":"Pancreatic Cancer, Non-small Cell Lung Cancer, Esophagogastric Cancer","enrollment":236},{"nctId":"NCT01063283","phase":"NA","title":"Dose Escalation of Bevacizumab With Ambulatory Blood Pressure Monitoring in Patients With Advanced Non-squamous NSCLC","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2010-03","conditions":"Advanced Non-squamous Non-Small Cell Lung Cancer","enrollment":20},{"nctId":"NCT00234052","phase":"PHASE2","title":"Carboplatin, Pemetrexed Disodium, and Bevacizumab in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2005-07-28","conditions":"Lung Cancer","enrollment":51},{"nctId":"NCT01263782","phase":"PHASE2","title":"BATTLE-FL: Front-Line Biomarker-Integrated Treatment Study in Non Small Cell Lung Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2011-05-17","conditions":"Lung Cancer","enrollment":64},{"nctId":"NCT03647956","phase":"PHASE2","title":"Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic NSCLC Patients After Failure of EGFR Tyrosine Kinase Inhibitors","status":"UNKNOWN","sponsor":"The University of Hong Kong","startDate":"2018-10-01","conditions":"NSCLC Stage IIIB, NSCLC Stage IV, EGFR Activating Mutation","enrollment":40},{"nctId":"NCT00614822","phase":"PHASE2","title":"Carboplatin, Bevacizumab and Pemetrexed in Advanced Non Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Christiana Care Health Services","startDate":"2007-11","conditions":"Non Small Cell Lung Cancer","enrollment":50},{"nctId":"NCT01344824","phase":"PHASE2","title":"Carboplatin, Pemetrexed Disodium, and Bevacizumab for Patients With Stage III or IV Non-Small Cell Lung Cancer Who Are Light/Never Smokers","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2010-03","conditions":"Lung Cancer","enrollment":38},{"nctId":"NCT00604461","phase":"PHASE1, PHASE2","title":"Carboplatin, Bevacizumab and Pemetrexed in the First-Line Treatment of Patients With Malignant Pleural Mesothelioma (MPM)","status":"TERMINATED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2007-10","conditions":"Mesothelioma","enrollment":13},{"nctId":"NCT00798603","phase":"PHASE2","title":"Pemetrexed, Carboplatin, and Bevacizumab as First-Line Therapy in Treating Older Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2008-12","conditions":"Lung Cancer","enrollment":65},{"nctId":"NCT01383148","phase":"PHASE2, PHASE3","title":"Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"Transgene","startDate":"2012-04","conditions":"Non-Small-Cell Lung Carcinoma","enrollment":222},{"nctId":"NCT00974584","phase":"PHASE1","title":"A Study of the Safety and Pharmacology Of PI3-Kinase Inhibitor GDC-0941 In Combination With Either Paclitaxel And Carboplatin (With or Without Bevacizumab) or Pemetrexed, Cisplatin, And Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2009-10","conditions":"Non-Squamous Non-Small Cell Lung Cancer","enrollment":65},{"nctId":"NCT01301716","phase":"PHASE1","title":"A Study of the Safety and Pharmacology of GDC-0980 in Combination With Either Paclitaxel and Carboplatin (With or Without Bevacizumab) or Pemetrexed and Cisplatin in Patients With Solid Tumors","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2011-09","conditions":"Solid Cancers","enrollment":75},{"nctId":"NCT02930954","phase":"PHASE2","title":"Gefitinib Combined With Chemotherapy or Antiangiogensis in Patients With Bim Deletion or Low EGFR Mutation Abundance","status":"UNKNOWN","sponsor":"Caicun Zhou","startDate":"2016-11","conditions":"Non-small-cell Lung Cancer","enrollment":180},{"nctId":"NCT01496742","phase":"PHASE2","title":"A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2012-04","conditions":"Non-Squamous Non-Small Cell Lung Cancer","enrollment":259},{"nctId":"NCT02829008","phase":"PHASE2","title":"Low -Dose-bevacizumab and Pemetrexed Versus TPC in Metastatic HER2-negative Breast Cancer Patients","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2016-04","conditions":"Metastatic Breast Cancer","enrollment":120},{"nctId":"NCT00766246","phase":"PHASE2","title":"Phase II Avastin Trial for Stage IIIB/IV NSCLC","status":"TERMINATED","sponsor":"Pharmatech","startDate":"2008-10","conditions":"Non-small Cell Lung Cancer Stage IIIB, Non-small Cell Lung Cancer Stage IV","enrollment":125},{"nctId":"NCT00976456","phase":"PHASE3","title":"Efficacy Study of Avastin® With Pemetrexed +/- Carboplatin to Treat Elderly Patients With Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"PD Dr. med. Wolfgang Schuette","startDate":"2009-09","conditions":"Non-squamous Non-small Cell Lung Cancer","enrollment":271},{"nctId":"NCT00762034","phase":"PHASE3","title":"A Study of Pemetrexed, Carboplatin and Bevacizumab in Participants With Nonsquamous Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2008-12","conditions":"Non-small Cell Lung Cancer","enrollment":939},{"nctId":"NCT00892710","phase":"PHASE2","title":"Trial of Poor Performance Status Patients (ToPPS)","status":"COMPLETED","sponsor":"SCRI Development Innovations, LLC","startDate":"2009-06","conditions":"Non Small Cell Lung Cancer","enrollment":172},{"nctId":"NCT01588704","phase":"PHASE2","title":"Neoadjuvant Pemetrexed, Carboplatin and Bevacizumab in Unresectable, Locally Advanced Lung Adenocarcinoma","status":"COMPLETED","sponsor":"Si-Yu Wang","startDate":"2012-04","conditions":"Lung Cancer","enrollment":42},{"nctId":"NCT01700400","phase":"PHASE1","title":"Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab to Treat Stage IV Lung Cancer","status":"COMPLETED","sponsor":"Cancer Research and Biostatistics Clinical Trials Consortium","startDate":"2012-09","conditions":"Non Small Cell Lung Cancer","enrollment":13},{"nctId":"NCT01303926","phase":"PHASE3","title":"Quality of Life Comparison in Advanced Non-squamous Non Small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Gruppo Oncologico Italia Meridionale","startDate":"2010-01","conditions":"Non-squamous Nonsmall Cell Neoplasm of Lung","enrollment":118},{"nctId":"NCT00407459","phase":"PHASE2","title":"Phase II Study of Bevacizumab, Pemetrexed and Carboplatin as First-Line Therapy in Malignant Pleural Mesothelioma","status":"COMPLETED","sponsor":"Armando Santoro, MD","startDate":"2007-09","conditions":"Mesothelioma","enrollment":77},{"nctId":"NCT00254319","phase":"PHASE2","title":"Previously Untreated Advanced Non-Small Cell Lung Cancer (NSCLC)","status":"UNKNOWN","sponsor":"The Cooper Health System","startDate":"","conditions":"Untreated Advanced Non-Small Cell Lung Cancer","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":33,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Avastin®","ALIMTA®","Carboplatin"],"phase":"phase_3","status":"active","brandName":"Bevacizumab + Pemetrexed + Carboplatin","genericName":"Bevacizumab + Pemetrexed + Carboplatin","companyName":"PD Dr. med. Wolfgang Schuette","companyId":"pd-dr-med-wolfgang-schuette","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses a monoclonal antibody to block tumor blood vessel formation while two chemotherapy agents work synergistically to kill cancer cells. Used for Non-squamous non-small cell lung cancer (NSCLC), first-line metastatic disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}